vs
FTC Solar, Inc.（FTCI）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
FTC Solar, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.7倍（$32.9M vs $19.6M），FTC Solar, Inc.净利率更高（-110.7% vs -177.4%，领先66.7%），FTC Solar, Inc.同比增速更快（148.9% vs -11.5%），FTC Solar, Inc.自由现金流更多（$-8.4M vs $-23.1M），过去两年FTC Solar, Inc.的营收复合增速更高（61.6% vs -12.2%）
FTC Solar是全球领先的太阳能跟踪系统供应商，主要研发、生产和销售太阳能跟踪支架、配套组件及相关软件解决方案，服务于公用事业级、工商业光伏项目领域，业务覆盖全球主要市场，助力客户提升光伏发电效率、降低项目成本。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
FTCI vs LAB — 直观对比
营收规模更大
FTCI
是对方的1.7倍
$19.6M
营收增速更快
FTCI
高出160.4%
-11.5%
净利率更高
FTCI
高出66.7%
-177.4%
自由现金流更多
FTCI
多$14.6M
$-23.1M
两年增速更快
FTCI
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.9M | $19.6M |
| 净利润 | $-36.4M | $-34.7M |
| 毛利率 | 14.9% | 48.5% |
| 营业利润率 | -17.2% | -168.5% |
| 净利率 | -110.7% | -177.4% |
| 营收同比 | 148.9% | -11.5% |
| 净利润同比 | -197.4% | -28.8% |
| 每股收益（稀释后） | $-2.31 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTCILAB
| Q4 25 | $32.9M | — | ||
| Q3 25 | $26.0M | $19.6M | ||
| Q2 25 | $20.0M | $21.8M | ||
| Q1 25 | $20.8M | $40.8M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $10.1M | $22.1M | ||
| Q2 24 | $11.4M | $22.5M | ||
| Q1 24 | $12.6M | $45.5M |
净利润FTCILAB
| Q4 25 | $-36.4M | — | ||
| Q3 25 | $-23.9M | $-34.7M | ||
| Q2 25 | $-15.4M | $-33.5M | ||
| Q1 25 | $-3.8M | $-26.0M | ||
| Q4 24 | $-12.2M | — | ||
| Q3 24 | $-15.4M | $-26.9M | ||
| Q2 24 | $-12.2M | $-45.7M | ||
| Q1 24 | $-8.8M | $-32.2M |
毛利率FTCILAB
| Q4 25 | 14.9% | — | ||
| Q3 25 | 6.1% | 48.5% | ||
| Q2 25 | -19.6% | 48.8% | ||
| Q1 25 | -16.6% | 48.4% | ||
| Q4 24 | -29.1% | — | ||
| Q3 24 | -42.5% | 54.9% | ||
| Q2 24 | -20.5% | 46.1% | ||
| Q1 24 | -16.7% | 53.1% |
营业利润率FTCILAB
| Q4 25 | -17.2% | — | ||
| Q3 25 | -29.6% | -168.5% | ||
| Q2 25 | -57.5% | -118.1% | ||
| Q1 25 | -50.8% | -80.8% | ||
| Q4 24 | -101.7% | — | ||
| Q3 24 | -147.8% | -120.9% | ||
| Q2 24 | -104.3% | -134.5% | ||
| Q1 24 | -99.3% | -132.2% |
净利率FTCILAB
| Q4 25 | -110.7% | — | ||
| Q3 25 | -92.0% | -177.4% | ||
| Q2 25 | -77.2% | -153.7% | ||
| Q1 25 | -18.4% | -63.8% | ||
| Q4 24 | -92.7% | — | ||
| Q3 24 | -151.5% | -122.0% | ||
| Q2 24 | -107.1% | -203.3% | ||
| Q1 24 | -69.7% | -70.6% |
每股收益（稀释后）FTCILAB
| Q4 25 | $-2.31 | — | ||
| Q3 25 | $-1.61 | $-0.09 | ||
| Q2 25 | $-1.18 | $-0.09 | ||
| Q1 25 | $-0.58 | $-0.07 | ||
| Q4 24 | $-0.95 | — | ||
| Q3 24 | $-1.21 | $-0.07 | ||
| Q2 24 | $-0.97 | $-0.12 | ||
| Q1 24 | $-0.70 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.1M | $129.4M |
| 总债务越低越好 | $9.9M | — |
| 股东权益账面价值 | $-43.0M | $399.7M |
| 总资产 | $111.8M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FTCILAB
| Q4 25 | $21.1M | — | ||
| Q3 25 | $24.4M | $129.4M | ||
| Q2 25 | $3.5M | $158.6M | ||
| Q1 25 | $5.9M | $150.9M | ||
| Q4 24 | $11.2M | — | ||
| Q3 24 | $8.3M | $210.6M | ||
| Q2 24 | $10.8M | $269.8M | ||
| Q1 24 | $14.0M | $287.1M |
总债务FTCILAB
| Q4 25 | $9.9M | — | ||
| Q3 25 | $16.6M | — | ||
| Q2 25 | $10.9M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | $9.5M | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益FTCILAB
| Q4 25 | $-43.0M | — | ||
| Q3 25 | $-13.7M | $399.7M | ||
| Q2 25 | $9.0M | $424.5M | ||
| Q1 25 | $15.5M | $454.6M | ||
| Q4 24 | $19.0M | — | ||
| Q3 24 | $30.4M | $489.3M | ||
| Q2 24 | $44.2M | $510.3M | ||
| Q1 24 | $55.2M | $577.3M |
总资产FTCILAB
| Q4 25 | $111.8M | — | ||
| Q3 25 | $111.5M | $539.6M | ||
| Q2 25 | $83.0M | $557.0M | ||
| Q1 25 | $84.1M | $579.6M | ||
| Q4 24 | $89.9M | — | ||
| Q3 24 | $91.7M | $681.5M | ||
| Q2 24 | $100.3M | $708.7M | ||
| Q1 24 | $115.0M | $777.7M |
负债/权益比FTCILAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | 0.65× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.0M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-8.4M | $-23.1M |
| 自由现金流率自由现金流/营收 | -25.7% | -118.1% |
| 资本支出强度资本支出/营收 | 1.3% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-34.6M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流FTCILAB
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $-14.6M | $-22.2M | ||
| Q2 25 | $-2.3M | $-20.7M | ||
| Q1 25 | $-8.5M | $-30.3M | ||
| Q4 24 | $-16.7M | — | ||
| Q3 24 | $-2.4M | $-27.9M | ||
| Q2 24 | $-3.8M | $-39.0M | ||
| Q1 24 | $-11.9M | $-62.5M |
自由现金流FTCILAB
| Q4 25 | $-8.4M | — | ||
| Q3 25 | $-15.1M | $-23.1M | ||
| Q2 25 | $-2.5M | $-22.6M | ||
| Q1 25 | $-8.6M | $-35.3M | ||
| Q4 24 | $-17.0M | — | ||
| Q3 24 | $-2.6M | $-30.1M | ||
| Q2 24 | $-4.5M | $-41.0M | ||
| Q1 24 | $-12.3M | $-63.3M |
自由现金流率FTCILAB
| Q4 25 | -25.7% | — | ||
| Q3 25 | -57.9% | -118.1% | ||
| Q2 25 | -12.4% | -103.6% | ||
| Q1 25 | -41.2% | -86.6% | ||
| Q4 24 | -128.6% | — | ||
| Q3 24 | -25.6% | -136.4% | ||
| Q2 24 | -39.2% | -182.2% | ||
| Q1 24 | -97.6% | -138.9% |
资本支出强度FTCILAB
| Q4 25 | 1.3% | — | ||
| Q3 25 | 1.7% | 4.5% | ||
| Q2 25 | 0.9% | 8.7% | ||
| Q1 25 | 0.4% | 12.4% | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 2.2% | 10.2% | ||
| Q2 24 | 6.1% | 8.6% | ||
| Q1 24 | 3.4% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTCI
| Products | $26.2M | 80% |
| Services | $6.7M | 20% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
